SEC Form 4 · accession 0001140361-15-004669

SANGAMO THERAPEUTICS, INC · SGMO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — VP, Therapeutic Dev. & CMO

Period of report

Feb 5, 2015

Accepted (ET)

Feb 6, 2015 · 7:50 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001001233

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F2,F3	Feb 5, 2015	M	11,798	$6.82	A	107,174	D
Common Stock^F2,F3	Feb 5, 2015	M	3,202	$3.45	A	110,376	D
Common Stock^F4,F2,F3	Feb 5, 2015	S	15,000	$12.93	D	95,376	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F5	$6.82	Feb 5, 2015	M	11,798	D	—	Dec 12, 2016	Common Stock	11,798	0	D
Employee Stock Option (Right to Buy)^F5	$3.45	Feb 5, 2015	M	3,202	D	—	Dec 9, 2018	Common Stock	3,202	110,798	D

F1The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 23, 2014.
F2Includes 11,666, 15,333 and 25,000 shares subject to RSUs granted on December 6, 2012, December 12, 2013 AND December 11, 2014 respectively, which will be issued as such units vest in accordance with their terms.
F3Includes 1,277 shares acquired by the Reporting Person on October 31, 2014 under the Issuer's Employee Stock Purchase Plan.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.61 to $13.12, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F5All shares underlying this option are vested and immediately exercisable.